Today, Avidity Biosciences Inc (NASDAQ: RNA) Takes Center Stage

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Avidity Biosciences Inc is $5.10B. A total of 0.61 million shares were traded on the day, compared to an average of 1.70M shares.

In the most recent transaction, LEVIN ARTHUR A sold 5,000 shares of RNA for 45.19 per share on Aug 19 ’24. After the transaction, the Director now owns 14,830 company shares. In a previous transaction on Aug 06 ’24, Boyce Sarah sold 28,000 shares at 43.35 per share. RNA shares that President and CEO owns now total 205,043.

Among the insiders who sold shares, LEVIN ARTHUR A disposed of 5,000 shares on Jul 19 ’24 at a per-share price of $45.01. This resulted in the Director holding 14,830 shares of RNA after the transaction. In another insider transaction, Boyce Sarah sold 28,000 shares at $39.93 per share on Jul 09 ’24. Company shares held by the President and CEO now total 205,043.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, RNA has a high of $48.80 and a low of $4.82.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RNA’s latest balance sheet shows that the firm has $405.54M in Cash & Short Term Investments as of fiscal 2021. There were $11.73M in debt and $29.66M in liabilities at the time. Its Book Value Per Share was $11.17, while its Total Shareholder’s Equity was $381.43M.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNA is Buy with a score of 4.89.

Most Popular

Related Posts